mutation in every sequencing read. Thus, millions of sequencing errors occur in every sequenced genome 5, 6 . These errors can be averaged to obtain a single consensus sequence for a population of cells; however, owing to this high error rate it is not feasible to reliably detect mutations present in fewer than 5% of cells. Molecular tagging of ssDNA before amplification [7] [8] [9] can reduce the frequency of erroneously called variants-but only by approximately 20-fold, as it cannot correct errors that occur in the first round of amplification and are propagated to subsequent copies 10 .
mutation in every sequencing read. Thus, millions of sequencing errors occur in every sequenced genome 5, 6 . These errors can be averaged to obtain a single consensus sequence for a population of cells; however, owing to this high error rate it is not feasible to reliably detect mutations present in fewer than 5% of cells. Molecular tagging of ssDNA before amplification [7] [8] [9] can reduce the frequency of erroneously called variants-but only by approximately 20-fold, as it cannot correct errors that occur in the first round of amplification and are propagated to subsequent copies 10 .
To overcome these limitations, we developed an alternative approach based on sequential rounds of capture with individual biotinylated DNA oligonucleotides in conjunction with duplex sequencing, which uses double-stranded, complementary molecular tags to separately label and amplify each of the two strands of individual duplex DNA molecules 10 . In duplex sequencing, mutations are scored only if they occur at the same position on both DNA strands, whereas amplification and sequencing errors, which appear in only one strand, are not scored.
As a demonstration, we attempted to detect rare mutations in the ABL1 gene that confer resistance to imatinib (Gleevec) therapy of chronic myeloid leukemia 11 . We synthesized 5′-biotinylated DNA oligonucleotides corresponding to exons 4-7 of ABL1 (Supplementary Table 1 ). Duplex sequencing adaptors containing complementary molecular tag sequences that identify each of the two strands of individual DNA molecules were ligated to sheared human genomic DNA (Online Methods). The product was then PCR amplified and hybridized to the pooled ABL1-targeting oligonucleotides, and hybridization was followed by recovery with streptavidin beads. Elution and sequencing revealed a 50,000-fold enrichment of the target; however, owing to the small size of the target, this enrichment resulted in only 2-5% of reads being on-target (Fig. 1a) . The recovered DNA was then subjected to iterative rounds of PCR and capture. In two independent experiments, two rounds of capture resulted in >97% of reads mapping to the ABL1 gene. A third round of capture provided no further improvement (Fig. 1a) .
The double-capture approach resulted in extremely high depth and uniformity of coverage (Fig. 1b) . Conventional capture yielded a maximum on-target depth of 25,000×. In contrast, with equivalent use of sequencing capacity, double capture gave up to 1,000,000× depth, with average and minimum depths of 830,000× and 250,000×, respectively. The duplex tags were then used to collapse into consensus sequences the PCR duplicates for which the two strands of individual DNA molecules were perfectly complementary. This yielded an average of more than 1,000 unique DNA molecules sampled at every nucleotide position within the ABL1 target (Supplementary Fig. 1 the detection of minority variants in mixed samples requires methods for enrichment and accurate sequencing of small genomic intervals. We describe an efficient approach based on sequential rounds of hybridization with biotinylated oligonucleotides that enables more than 1-million-fold enrichment of genomic regions of interest. in conjunction with error-correcting double-stranded molecular tags, our approach enables the quantification of mutations in individual dna molecules.
Diseases such as cancer or viral infections do not manifest as a single population of cells but rather as a heterogeneous mixture of subclonal populations 1 . Although massively parallel sequencing has made it feasible to scan whole genomes for clonal nucleotide variations, this approach cannot readily delineate the heterogeneity of mutations within a cell population. In order to detect rare, subclonal mutations, sequencing must be carried out to depths that can be prohibitively expensive, and at low frequencies it becomes difficult or impossible to distinguish sequencingrelated errors from true variation. We overcome these challenges by coupling extensive purification of targeted sequences with highly accurate DNA sequencing.
Targeted capture approaches 2 sequence large genomic regions (typically hundreds of kilobases to several megabases); sequencing at great depth is impractical for targets of this size owing to the large amount of sequencing capacity that would be required. These approaches do not scale to small targets (<50 kb) and typically result in recovery of targeted DNA sequences of 5% or less. Small targets can be amplified by methods such as PCR or molecular inversion probes 3 ; however, these methods are error prone and generate artifactual mutations that overwhelm the detection of subclonal variants 4 .
Detection of subclonal and random mutations in a target gene also requires extremely accurate sequencing. High-throughput sequencing has a high error rate of 0.1-1%, averaging one artifactual We used our protocol to sequence the ABL1 gene from an individual with chronic myeloid leukemia who relapsed after treatment with the targeted therapy imatinib. Conventional highthroughput sequencing was unable to resolve any mutations in the sample (Fig. 2a) . Even stringent quality filtering (requiring a minimum Phred quality score of 50) was unable to remove background errors, as many sequencing errors occur during PCR amplification and thus cannot be removed by quality filtering 10 . In contrast, duplex sequencing revealed a single mutation with a mutant fraction of 1% (Fig. 2b) . This mutation, E279K, is known to confer imatinib resistance 11 .
Alternative methods to detect subclonal mutations have been described that result in multiple copies of ssDNA linked together by concatemerization 12 or tagged with a molecular identifier sequence 8, 9 . These approaches are inherently more error prone than duplex sequencing because they use information from only one of the two DNA strands and thus have less capability for error correction. To compare our double-stranded tagging approach to these methods, we reanalyzed our data using information from only one of the two tagged strands, which we refer to as single-strand consensus sequences 10 . This analysis resulted in mutations at hundreds of positions in the ABL1 target (Supplementary Fig. 2) , in contrast to the one true mutation that was found by duplex sequencing. The discrepancy indicates that >99% of mutations identified by the single-stranded tagging approach are artifacts.
We next determined whether our approach could scale to multiple targets. We obtained biotinylated oligonucleotides corresponding to the coding exons of the five human replicative DNA polymerases 13 (total target size, 19.4 kb) and applied the doublecapture approach to DNA extracted from histologically normal human prostate and colon. More than 90% of reads mapped to the targeted genes, revealing mutation frequencies of 1 × 10 −7 to 4 × 10 −7 (Supplementary Table 2) . Among the mutations, six were in introns and two changed the coding sequence of DNA polymerase epsilon (Supplementary Table 3) . The frequency of mutations is in accord with prior estimates 14, 15 of the spontaneous mutation rate in human cells and thus could be the result of multiple rounds of cell division and endogenous mutagenic processes. Alternatively, these mutations could represent artifacts in our assay. However, the error frequency of duplex sequencing has been estimated to be <4 × 10 −10 , as complementary errors would need to occur in both strands to be scored 10 .
Our approach allows for the study of small genomic regions, such as individual human exons or viral sequences present at low levels in human samples. Owing to the high level of enrichment, significant depth can be obtained with modest sequencing. For example, a 1-kb target can be sequenced to 100,000-fold depth with 4 × 10 5 paired-end 125-nt reads, and thus hundreds of samples can be sequenced simultaneously on a single lane of an Illumina HiSeq 2500. The approach is therefore highly scalable and cost effective for sequencing small targets. Duplex sequencing on larger targets, such as whole exomes, is also possible in principle with a greater use of sequencing capacity. conditions, the full exome from 100 individual cells would require approximately 2 × 10 11 nt of sequence capacity, which is within the output range of currently available sequencers. Our ABL1 results indicate that it is possible to assay for the presence of preexisting subclones encoding resistance to targeted cancer therapies, which would be expected to clonally expand in the presence of corresponding inhibitors. Armed with this knowledge, physicians could treat patients with drugs chosen for their lack of any detectable resistance. Targeted, high-accuracy capture has additional applications in a wide range of fields, including the detection of tumor-specific circulating DNA as a biomarker for cancer treatment 16 , the detection of minimal residual disease in hematologic malignancies 17 , confirming candidate subclonal mutations that are found by conventional sequencing, analysis of mutational processes in cancer 18 and testing for low-level resistance mutations in viral populations. Moreover, as the extreme accuracy of the approach results in a theoretical need of only 1× coverage of a genome to obtain an accurate sequence, we anticipate applications in settings where sample availability is extremely limited, such as paleogenomics, forensics and the study of circulating tumor cells. online methods Human subjects approval. Use of human samples was approved by the Institutional Review Board at the University of Washington. Informed consent was obtained from patients who contributed samples.
DNA isolation. Genomic DNA was extracted from peripheral blood mononuclear cells or tissue by high-salt extraction using the Agilent DNA extraction kit #200600.
Ligation of duplex sequencing adaptors. Duplex sequencing was initially described with use of A-tailed adaptors 10, 19 ; we have since found that T-tailed adaptors result in improved ligation efficiency, and we have published a detailed protocol for their synthesis and use 20 . In brief, DNA was sheared, end repaired, A tailed and then ligated to T-tailed duplex sequencing adaptors using a 20× molar excess of adaptors relative to A-tailed DNA molecules. Following reaction cleanup with 1.0 volumes of Ampure XP beads (Agencourt), the adaptor-ligated DNA was PCR amplified for five cycles with the KAPA Biosystems hot-start high-fidelity kit using primers mws13 and mws20 (Supplementary Table 1 ). 240 ng of input DNA were used in each 100-µl PCR reaction, with 2-8 PCR reactions performed per sample. Owing to the small amount of on-target DNA present in the starting sample, multiple PCR reactions are needed to amplify sufficient on-target DNA for capture. Each PCR reaction results in sequence data representing approximately 500 independent genomes; the number of PCR reactions performed can be adjusted depending on the sequencing coverage desired. The products from all reactions were pooled and purified with 1.2 volumes of Ampure XP beads, with a final elution volume of 50 µl.
Targeted capture. One-third of the total amount of adaptorligated DNA generated by PCR was combined with 5 µg of Cot-I DNA (Invitrogen) and 1 nmol each of blocking oligonucleotides mws60 and mws61. The mixture was completely lyophilized and then resuspended in 2.5 µl water, 7.5 µl NimbleGen 2× hybridization buffer and 3 µl NimbleGen hybridization component A. The mixture was heated to 95 °C for 10 min, the temperature was adjusted to 65 °C and 3 pmol of pooled biotinylated oligonucleotides were added (Integrated DNA Technologies).
